Login / Signup

Comparison of nalbuphine and sufentanil for colonoscopy: A randomized controlled trial.

Chaoyi DengXiao WangQianmei ZhuYanming KangJinlin YangHeng Wang
Published in: PloS one (2017)
Nalbuphine can be considered as a reasonable alternative to sufentanil in patients undergoing colonoscopy. Doses in the range of 0.1-0.2 mg/kg are recommended. The decreased risks of respiratory depression and apnea make nalbuphine suitable for patients with respiratory problems.
Keyphrases
  • patients undergoing
  • mental health
  • colorectal cancer screening
  • obstructive sleep apnea
  • depressive symptoms
  • respiratory tract
  • human health
  • sleep quality
  • risk assessment